Our Programs

Hereditary Angioedema (HAE)

BioCryst is seeking to revolutionize treatment for Hereditary Angioedema (HAE) by developing orally-administered drugs to prevent and control HAE attacks

Our lead compound, berotralstat (BCX7353), is designed to be an oral, once-daily capsule that prevents attacks by inhibiting plasma kallikrein. In December 2019, BioCryst submitted a new drug application to the U.S. Food and Drug Administration seeking approval of oral, once-daily berotralstat for the prevention of HAE attacks.

The company plans to submit a marketing authorization application for berotralstat for the prevention of HAE attacks with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the European Medicines Agency (EMA) in the first quarter of 2020.

Pursuing Fibrodysplasia Ossificans Progressiva (FOP)

Enzyme inhibition is a promising target in our race to help patients with FOP live normal lives.

Learn More